Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-25T18:39:29.097Z Has data issue: false hasContentIssue false

Practical pharmacotherapy for anxiety

Published online by Cambridge University Press:  02 January 2018

Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Anxiety is a very common and disabling condition which has serious consequences for patients, their families and society in general. The past decade has witnessed an increase in the recognition and understanding of the problem but considerable confusion and debate remains over attitudes towards treatment. The background to this controversy dates from the late 1980s when widespread and vehement criticism of doctors and drug companies over the use of benzodiazepines began. Although the litigation was unsuccessful, it resulted in a pervading feeling of uncertainty (both within the medical profession and among patients) about prescribing or taking any drug as a treatment for anxiety. The situation has been further confounded by the split that has occurred between the proponents of pharmacological and psychological approaches to management. These controversies have left the practising clinician in an unenviable position, with few practical or relevant guidelines to follow. Developments over recent years, however, should put an end to this confusion; new pharmacotherapies such as the selective serotonin reuptake inhibitors (SSRIs) and buspirone, and older ones such as the tricyclic antidepressants (TCAs), have emerged as effective alternatives to the benzodiazepines and have been paralleled by a similar growth in effective and available psychological treatments, particularly cognitive and cognitive–behavioural therapy. This progress seems set to continue with the rapid expansion of knowledge about the brain circuits and transmitters regulating anxiety that is now emerging from imaging studies.

Type
Research Article
Copyright
Copyright © The Royal College of Psychiatrists 1997 

References

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). Washington, DC: APA.Google Scholar
Forster, P. & Marmar, C. (1991) Benzodiazepines in acute stress disorders. In Benzodiazepines in Clinical Practice: Risks and Benefits (eds Roy-Byrne, P. P. & Cowley, D. S.) pp. 7389. Washington, DC: American Psychiatric Press.Google Scholar
Klein, D. F. (1964) Delineation of two drug responsive anxiety syndromes. Psychopharmacologica, 5, 397408.Google Scholar
Nutt, D. J. & Glue, P. (1991) Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. In Psychopharmacology of Anxiolytics and Antidepressants (ed. File, S.) pp. 128. New York: Pergamon.Google Scholar
Nutt, D. J., Bell, C. B. & Potokar, J. P. (1995) Drug treatment of chronic anxiety. In Pharmacological Management of Chronic Psychiatric Disorders (eds Lader, M. H. & Ancill, R.) London: Baillière-Tindall.Google Scholar
Petursson, H. & Lader, M. H. (1984) Dependence on Tranquillizers. London: Oxford University Press.Google Scholar
Rickeis, K., Schweizer, E., Case, W. G. et al (1990) Long-term therapeutic use of benzodiazepines. I: Effects of abrupt discontinuation. Archives of General Psychiatry, 47, 899907.Google Scholar
Rickeis, K., Downing, R. & Schweizer, E. (1993) Antidepressants for the treatment of GAD. Archives of General Psychiatry, 50, 884895.Google Scholar
Schweizer, E., Rickeis, K. & Weiss, (1993) Maintenance drug treatment for panic disorder. Archives of General Psychiatry, 50, 6168.Google Scholar
Schweizer, E., Rickeis, K., Case, W. G. et al (1990) Long-term therapeutic use of benzodiazepines. II: Effects of gradual taper. Archives of General Psychiatry, 47, 908915.CrossRefGoogle ScholarPubMed
Tyrer, P., Candy, J. & Kelly, D. (1973) Phenelzine in phobic anxiety: a controlled trial. Psychological Medicine, 3, 120124.Google Scholar
Tyrer, P., Owen, R. & Dawling, S. (1983) Gradual withdrawal of diazepam after long-term therapy. Lancet, i, 14021406.Google Scholar
Versiani, M., Nardi, A. E. & Mundim, F. D. (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry, 161, 353360.Google Scholar
World Health Organization (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD–10). Geneva: WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.